Staff Contact: Tom DiLenge, General Counsel & Head of Public Policy, firstname.lastname@example.org 
Subject Matter/Jurisdiction: The committee oversees domestic intellectual property (IP) issues (e.g., patent term, patent reform, Patent and Trademark Office matters, judiciary, and IP budgetary issues), international IP issues (e.g., GATT, TRIPS, WTO, WHO, CBD), and the Biojudiciary Project initiative.
Alex Azar, President, Eli Lilly USA
Ian Clark, Chief Executive Officer, Genentech, Inc.
Stan Crooke, Chairman & CEO, Isis Pharmaceuticals
Jeff Hatfield, Chief Executive Officer, Vitae Pharmaceuticals, Inc.
Russell Herndon, President & CEO, Hydra Biosciences, Inc.
Emer Leahy, President and CEO, PsychoGenics, Inc.
John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Arlene Morris, Chief Executive Officer, Syndax
David Pyott, Chairman & CEO, Allergan, Inc.
Gerald Steiner, Executive VP, Commercial Acceptance, Monsanto Company
Ronald Stotish, Chief Executive Officer, Aqua Bounty Technologies, Inc.
Harold Van Wart, President, CEO & Director, Metabolex, Inc.